Upsher-Smith inks ophthalmic, otic generics deal
Upsher-Smith Labs will be marketing and distributing six ophthalmic and otic generics through a new agreement with a pharmaceutical partner. The Maple Grove, Minn.-based company’s collaboration will see it market and distribute products whose combined annual sales total more than $1.6 billion annually, according to IQVIA data for the 12 months ended March 2018.
Upsher-Smith said the collaboration was part of its efforts to expand its generics pipeline and strategic relationships. Under the agreement, the company will register the products with the Food and Drug Administration, with its partner manufacturing the products exclusively for Upsher-Smith upon approval.
“Upsher-Smith is committed to significantly expanding its pipeline and diversifying its product portfolio through both internal development and strategic partnerships,” said Rusty Field, president and CEO of Upsher-Smith. “This new agreement will add six new products and expand the portfolio to include both ophthalmic and otic agents.”
Upsher-Smith said the collaboration was part of its efforts to expand its generics pipeline and strategic relationships. Under the agreement, the company will register the products with the Food and Drug Administration, with its partner manufacturing the products exclusively for Upsher-Smith upon approval.
“Upsher-Smith is committed to significantly expanding its pipeline and diversifying its product portfolio through both internal development and strategic partnerships,” said Rusty Field, president and CEO of Upsher-Smith. “This new agreement will add six new products and expand the portfolio to include both ophthalmic and otic agents.”